Pasotuxizumab, a BiTE® immune therapy for castration-resistant prostate cancer: Phase I, dose-escalation study findings. - Hummel HD; Kufer P; Grüllich C; Seggewiss-Bernhardt R; Deschler-Baier B; Chatterjee M; Goebeler ME; Miller K; de Santis M; Loidl W; Dittrich C; Buck A; et al. (Immunotherapy, 2021)